YOLFTbeta
Humasis Co. Ltd

Humasis Co. Ltd

205470 · KQ · Healthcare / Medical Devices

2,520.00KRW+205.00 (+8.86%)

Price History

Full chart

Market Stats

Previous Close2,315.00
Open2,290.00
Day Range2,285.00 – 2,995.00
52-Week Range1,898.00 – 6,770.00
Volume762.39K
Market Cap58.70B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.00
50-Day Avg2,670.10
200-Day Avg3,580.25

About

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus. In addition, it offers diagnostic equipment, such as urinalysis, blood glucose meters, and immunodiagnostics tools. Further, it provides other test kits, such as Cotinine to test cotinine in urine; and G6PD, an in vitro diagnostic test that can detect glucose-6-phosphate dehydrogenase in human whole blood. The company was founded in 2000 and is headquartered in Anyang-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Sung-gon Kim
  • Employees60
  • HeadquartersHogye-dong, Shinwon Vision Tower, Anyang-si, South Korea, 14042, Korea
  • Websitehttps://www.humasis.com

Leadership

  • Mr. Sung-gon KimCEO & Director · b. 1971

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0008.51B9.66B9.15B45.72B321.83B471.27B13.83B25.41B30.11B
Growth (%)----+13.51%-5.25%+399.61%+603.96%+46.44%-97.07%+83.79%+18.49%
Cost of Revenue39.76M105.30M04.89B5.98B5.21B14.86B111.44B215.37B50.77B24.28B27.88B
Gross Profit-39.76M-105.30M03.62B3.68B3.94B30.86B210.39B255.90B-36.94B1.13B2.23B
Gross Margin---42.57%38.10%43.07%67.50%65.37%54.30%-267.16%4.45%7.41%
Operating Expense0-52.65M46.71M3.76B4.71B4.82B5.36B16.80B46.58B23.65B47.00B16.28B
Operating Income-39.76M-52.65M-46.71M-137.20M-1.03B-875.26M25.51B193.59B209.33B-60.60B-45.86B-14.05B
Operating Margin----1.61%-10.69%-9.57%55.79%60.15%44.42%-438.23%-180.47%-46.64%
EBITDA--------242.50B-57.39B-34.26B-16.07B
EBITDA Margin--------51.46%-415.04%-134.82%-53.36%
Net Income5.96M137.00M110.59M-4.72B-852.81M-1.23B21.08B151.20B182.63B-55.42B-30.44B-15.62B
Net Income Margin----55.44%-8.83%-13.40%46.12%46.98%38.75%-400.83%-119.79%-51.87%
R&D------1.46B3.37B5.23B4.13B1.53B406.85M
R&D as % of Total Revenue------3.19%1.05%1.11%29.89%6.01%1.35%
Interest Expense000000265.78M117.61M93.95M67.86M1.03B2.23B
Interest Expense % of Total Revenue---0.00%0.00%0.00%0.58%0.04%0.02%0.49%4.04%7.40%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--12.13B28.32B34.29B36.49B68.35B340.71B467.53B347.31B331.92B327.03B
Total Liabilities4.16B4.23B1.26B12.73B18.17B21.24B19.51B138.71B120.80B59.98B102.65B91.66B
Total Equity20.96B21.23B10.86B15.60B16.13B15.24B48.84B202.01B346.73B287.33B229.26B215.06B
Cash-----3.79B14.28B1.10M942.24K12.30B1.25M15.72B
Total Debt-----7.30B11.90B-----
Net Debt-----10.67B----3.61B-

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-72.93M160.42M151.11M-2.97B-747.08M779.58M14.30B205.02B202.60B-55.48B30.37B10.14B
Investing Cash Flow-24.12B-1.90B-150.98M-9.81B-6.12B-1.27B-5.95B-31.42B-322.68B54.15B-4.52B-
Financing Cash Flow56.61B2.30B2.30B13.72B7.00B2.68B2.68B-12.05B-37.39B-5.93B-28.90B-
Capital Expenditure0001.25B990.27M2.99B15.08B18.11B44.63B23.31B1.38B443.09M
Free Cash Flow-------786.78M186.91B157.96B-78.80B23.64B9.70B
Dividends Paid--------6.84B0--
FCF to OCF-------5.50%91.16%77.97%142.02%77.83%95.63%
Dividend Paid to FCF--------4.33%0.00%--

Earnings

Report DateSep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate---------------------------------------
EPS Actual-33.7517.5217.4213.49-126.25-353.24-28.26-9.97-22.7220.85-11.77-126.6115.7267.6312.44277.6424.43466.58367.88347.062059.222753.125841.752555.15355.43-1920.47-303.87-818.0248.98-1104.6863.5549.32-119.84-1347.49-76.12-267.0330.01-377.11153.23
Surprise---------------------------------------
Timing---------------------------------------

Key Statistics & Ratios

Market Cap58.70B
Enterprise Value-97.62B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.85
Price / Book0.28
Revenue (TTM)31.73B
Gross Profit (TTM)3.14B
EBITDA-8.45B
Profit Margin-49.19%
Operating Margin-42.79%
Return on Equity-10.97%
Return on Assets-2.15%
Shares Outstanding22.62M
Shares Float15.82M
Beta-0.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20221×
50.00Dec 28, 2022
20211×
250.00Dec 29, 2021

Stock Splits

  • May 11, 20261:5
  • Mar 24, 20234:1